Table 1

Clinical features of children with congenital leukaemia and transient myeloproliferative disorder

PatientYear of diagnosisAge in days (sex)Clinical phenotypeSkin involvementWhite cell count ×109/l (% blasts)Bone marrow blasts (%)ImmunphenotypeKaryotypeSpecific treatmentOutcomeDiagnosis
ALL, acute lymphoblastic leukaemia; AML, acute myeloid leukaemia; DAT, daunorubicin, cytarabine, thioguanine; RSV, respiratory syncytial virus; TdT, terminal deoxynucleotidyl transferase; TMD, transient myeloproliferative disorder; UD BMT, unrelated donor bone marrow transplant.
1198442 (F)Normalnodules66 (7)30Not done46 XXDATDied age 46 daysAML M4
219940 (F)DownNo119 (100)Not doneNot doneNot doneNoneDied age 1 dayAML M7
3199417 (M)DownNo9 (2)12Not done47 XY, +21NoneRecovered spontaneouslyTMD
419950 (M)NormalNo39 (90)Not doneNot done46 XY 47 XY, +21NoneRecovered spontaneously. No features of Down’s syndromeTMD
5199688 (F)NormalNo50 (100)95CD19, HLADR, TdT positive CD10/13/33/3/7 negative46 XX, t(4;11)Infant ALL regimenRemission UD BMT Relapse Died age 2 yearsNull ALL
6199670 (F)DownNo6 (1)15CD13/33/34/7 positive CD10/19/3, TdT negative47 XX, +21None DAT for relapseRecovered Relapsed AML Remission persistsTMD and AML
719978 (M)DownNo90 (100)90Not done46 XYCytarabine 5mgBlast count fellTMD
47 XY, +21Cytarabine 7.5 mg as single dosesComplete recovery
819970 (F)NormalNo354 (100)90CD13/33 positive CD3/10/19/61 negative46 X, ins(X;6)Cytarabine 7.5 mg as single doseRemission persistsAML M0 ?Null ALL
Hybrid ALL and AML regimen UD BMT
9199954 (M)NormalNo100 (100)Not doneCD19 positive CD10/3/13/33, Tdt negative46 XY, t(11;19)Infant ALL regimenRemission RSV pneumonitis Died age 1 yearNull ALL